ASH Clinical News
@ashclinicalnews.bsky.social
A magazine from @ash-hematology.bsky.social offering news and views for the broader hematology/oncology community.
www.ASHClinicalNews.org
www.ASHClinicalNews.org
A 600 mg daily dose of the menin inhibitor #ziftomenib, combined with venetoclax and azacitidine, demonstrated robust clinical activity in patients with newly diagnosed, NPM1-mutated #AcuteMyeloidLeukemia #AML at an 84% CRc and an MRD-negative rate of 54%: https://ow.ly/E5Nb50XMwL0
#HemeSky #OncSky
#HemeSky #OncSky
December 19, 2025 at 4:05 PM
A 600 mg daily dose of the menin inhibitor #ziftomenib, combined with venetoclax and azacitidine, demonstrated robust clinical activity in patients with newly diagnosed, NPM1-mutated #AcuteMyeloidLeukemia #AML at an 84% CRc and an MRD-negative rate of 54%: https://ow.ly/E5Nb50XMwL0
#HemeSky #OncSky
#HemeSky #OncSky
For patients with #PolycythemiaVera, #rusfertide provided durable, sustained hematocrit control that stayed below 43% and reduced #phlebotomy requirements up to 52 weeks, with 61.9% of patients remaining ineligible for phlebotomy between 0-52 weeks: https://ow.ly/KYiZ50XKVRT
#HemeSky #MedSky
#HemeSky #MedSky
December 17, 2025 at 6:02 PM
For patients with #PolycythemiaVera, #rusfertide provided durable, sustained hematocrit control that stayed below 43% and reduced #phlebotomy requirements up to 52 weeks, with 61.9% of patients remaining ineligible for phlebotomy between 0-52 weeks: https://ow.ly/KYiZ50XKVRT
#HemeSky #MedSky
#HemeSky #MedSky
For patients with myeloid/lymphoid #neoplasms with FGFR1 rearrangements, #pemigatinib led to high rates of complete clinical and cytogenetic responses in chronic-phase disease, at 96% and 88%, respectively, with encouraging activity in blast-phase disease: https://ow.ly/UKCT50XKhvX
#HemeSky #OncSky
#HemeSky #OncSky
December 16, 2025 at 4:02 PM
For patients with myeloid/lymphoid #neoplasms with FGFR1 rearrangements, #pemigatinib led to high rates of complete clinical and cytogenetic responses in chronic-phase disease, at 96% and 88%, respectively, with encouraging activity in blast-phase disease: https://ow.ly/UKCT50XKhvX
#HemeSky #OncSky
#HemeSky #OncSky
According to a recent analysis of the iStopMM study, individuals with smoldering multiple myeloma #MMsm (SMM) had a 36% higher risk of infections compared with individuals with MGUS or those without either SMM or MGUS: https://ow.ly/RWcE50XH9Nz
#HemeSky #myeloma
#HemeSky #myeloma
December 12, 2025 at 3:01 PM
According to a recent analysis of the iStopMM study, individuals with smoldering multiple myeloma #MMsm (SMM) had a 36% higher risk of infections compared with individuals with MGUS or those without either SMM or MGUS: https://ow.ly/RWcE50XH9Nz
#HemeSky #myeloma
#HemeSky #myeloma
#ASH25 In patients with #myelofibrosis, the mutant CALR-specific monoclonal antibody INCA33989 was well tolerated as monotherapy or in combination with #ruxolitinib, with 37% and 30% of patients having SVR25 and SVR35, respectively, at 24 weeks: https://ow.ly/4FX950XF6zZ
#HemeSky #MedSky
#HemeSky #MedSky
December 8, 2025 at 7:30 PM
#ASH25 In patients with #myelofibrosis, the mutant CALR-specific monoclonal antibody INCA33989 was well tolerated as monotherapy or in combination with #ruxolitinib, with 37% and 30% of patients having SVR25 and SVR35, respectively, at 24 weeks: https://ow.ly/4FX950XF6zZ
#HemeSky #MedSky
#HemeSky #MedSky
#ASH25 The BCL2 inhibitor #sonrotoclax produced good responses in patients with treatment-naïve CLL/SLL when combined with #obinutuzumab, with ORRs of 89% across all patients and 93% at a 320 mg dose: https://ow.ly/M8uB50XF6zT
#HemeSky #MedSky
#HemeSky #MedSky
December 8, 2025 at 2:30 PM
#ASH25 The BCL2 inhibitor #sonrotoclax produced good responses in patients with treatment-naïve CLL/SLL when combined with #obinutuzumab, with ORRs of 89% across all patients and 93% at a 320 mg dose: https://ow.ly/M8uB50XF6zT
#HemeSky #MedSky
#HemeSky #MedSky
#ASH25 In the first head-to-head study of the two drugs, #pirtobrutinib was found to produce ORRs that were noninferior to those seen with #ibrutinib in both the intent-to-treat and R/R population of patients with #CLL: https://ow.ly/WIEg50XExWA
#HemeSky #OncSky
#HemeSky #OncSky
December 7, 2025 at 8:30 PM
#ASH25 In the first head-to-head study of the two drugs, #pirtobrutinib was found to produce ORRs that were noninferior to those seen with #ibrutinib in both the intent-to-treat and R/R population of patients with #CLL: https://ow.ly/WIEg50XExWA
#HemeSky #OncSky
#HemeSky #OncSky
#ASH25 Among patients with #ChronicLymphocyticLeukemia, fixed-duration targeted treatment using venetoclax-based combinations was found to achieve efficacy comparable to #BTKi therapy, with 3-year PFS ranging from 79% to 81% across all treatment arms: https://ow.ly/LOkJ50XExRg
#HemeSky #OncSky
#HemeSky #OncSky
December 7, 2025 at 5:30 PM
#ASH25 Among patients with #ChronicLymphocyticLeukemia, fixed-duration targeted treatment using venetoclax-based combinations was found to achieve efficacy comparable to #BTKi therapy, with 3-year PFS ranging from 79% to 81% across all treatment arms: https://ow.ly/LOkJ50XExRg
#HemeSky #OncSky
#HemeSky #OncSky
#ASH25 Based on findings from the largest prospective analysis of #renal impairment in patients with #PolycythemiaVera (PV), a history of #thromboembolism, high-risk PV, and elevated LDH were found to be associated with rapid decline in #kidney function: https://ow.ly/AmqA50XExMH
#HemeSky #MedSky
#HemeSky #MedSky
December 7, 2025 at 3:00 PM
#ASH25 Based on findings from the largest prospective analysis of #renal impairment in patients with #PolycythemiaVera (PV), a history of #thromboembolism, high-risk PV, and elevated LDH were found to be associated with rapid decline in #kidney function: https://ow.ly/AmqA50XExMH
#HemeSky #MedSky
#HemeSky #MedSky
A frailty-score-adapted treatment regimen of an oral PI/IMiD combination improved early treatment cessation, PFS, and OS in unfit patients with #MultipleMyeloma #MMsm but not in frail patients, according to research to presented at #ASH25: https://ow.ly/rtun50XCYcp
#HemeSky #MyelomaSky
#HemeSky #MyelomaSky
December 6, 2025 at 8:00 PM
A frailty-score-adapted treatment regimen of an oral PI/IMiD combination improved early treatment cessation, PFS, and OS in unfit patients with #MultipleMyeloma #MMsm but not in frail patients, according to research to presented at #ASH25: https://ow.ly/rtun50XCYcp
#HemeSky #MyelomaSky
#HemeSky #MyelomaSky
#ASH25 Anito-cel, a new anti-BMCA #CARTcell therapy with a unique D-domain binder that may lead to more therapeutic efficacy, was found to produce strong rates of response in patients with R/R #MultipleMyeloma #MMsm, with an ORR of 97% and CR/sCR of 68%: https://ow.ly/P9Gj50XCNnl
#HemeSky #OncSky
#HemeSky #OncSky
December 6, 2025 at 5:00 PM
#ASH25 Anito-cel, a new anti-BMCA #CARTcell therapy with a unique D-domain binder that may lead to more therapeutic efficacy, was found to produce strong rates of response in patients with R/R #MultipleMyeloma #MMsm, with an ORR of 97% and CR/sCR of 68%: https://ow.ly/P9Gj50XCNnl
#HemeSky #OncSky
#HemeSky #OncSky
Results from the phase II Shorespan-004 trial, to be presented at #ASH25, indicate that oral #bomedemstat effectively reduced hematocrit to less than 45% by week 36 in 45% of patients with previously treated #PolycythemiaVera: https://ow.ly/2bmS50XCMyM
#HemeSky #MedSky
#HemeSky #MedSky
December 6, 2025 at 2:00 PM
Results from the phase II Shorespan-004 trial, to be presented at #ASH25, indicate that oral #bomedemstat effectively reduced hematocrit to less than 45% by week 36 in 45% of patients with previously treated #PolycythemiaVera: https://ow.ly/2bmS50XCMyM
#HemeSky #MedSky
#HemeSky #MedSky
Imaging's Hidden Cost: There may be a link between #medical #imaging and childhood #BloodCancers. A retrospective cohort study found that 10.1% of #hematologic cancers in children may be caused by #radiation exposure from medical imaging.
#HemeSky #OncSky
#HemeSky #OncSky
December 5, 2025 at 3:01 PM
Imaging's Hidden Cost: There may be a link between #medical #imaging and childhood #BloodCancers. A retrospective cohort study found that 10.1% of #hematologic cancers in children may be caused by #radiation exposure from medical imaging.
#HemeSky #OncSky
#HemeSky #OncSky
The December issue is available now! Check out the link below to read articles on #isatuximab for R/R AL #amyloidosis, ATRA-ATO combination therapy for APL, #pemigatinib for myeloid & lymphoid #neoplasms with FGFR1 rearrangements, and more: https://ow.ly/fzzm50XARLQ
December 3, 2025 at 2:10 PM
The December issue is available now! Check out the link below to read articles on #isatuximab for R/R AL #amyloidosis, ATRA-ATO combination therapy for APL, #pemigatinib for myeloid & lymphoid #neoplasms with FGFR1 rearrangements, and more: https://ow.ly/fzzm50XARLQ
A longer time from T-cell collection to infusion of #CARTcell therapy was associated with worse outcomes, particularly with regard to PFS and OS, in patients with R/R #DLBCL, according to findings from a small retrospective trial conducted in Japan: https://ow.ly/SwTh50XAlhw
December 2, 2025 at 4:01 PM
A longer time from T-cell collection to infusion of #CARTcell therapy was associated with worse outcomes, particularly with regard to PFS and OS, in patients with R/R #DLBCL, according to findings from a small retrospective trial conducted in Japan: https://ow.ly/SwTh50XAlhw
Health Care Musical Chairs: #Burnout and dissatisfaction among #healthcare workforce may lead to lower retention rates. Results from the Harris Poll found that 55% of health care workers plan to switch jobs in 2026.
#HemeSky #MedSky
#HemeSky #MedSky
November 28, 2025 at 3:10 PM
Health Care Musical Chairs: #Burnout and dissatisfaction among #healthcare workforce may lead to lower retention rates. Results from the Harris Poll found that 55% of health care workers plan to switch jobs in 2026.
#HemeSky #MedSky
#HemeSky #MedSky
See what's to come in the December issue of ASH Clinical News! Highlights of next month's issue include articles on the past, present, and future of #hematology, rethinking the classification of #myeloid #neoplasms, early treatment in #MCL, and more: https://ow.ly/ngmg50XxL5o
#HemeSky
#HemeSky
November 26, 2025 at 2:05 PM
See what's to come in the December issue of ASH Clinical News! Highlights of next month's issue include articles on the past, present, and future of #hematology, rethinking the classification of #myeloid #neoplasms, early treatment in #MCL, and more: https://ow.ly/ngmg50XxL5o
#HemeSky
#HemeSky
According to recent findings, erythroid-predominant #MyelodysplasticSyndromes #MDS, found to be characterized by frequent multi-hit #TP53 alterations and BCL-XL upregulation, is also associated with poor outcomes after #venetoclax-based therapy: https://ow.ly/HAMr50XwV6o
#HemeSky
#HemeSky
November 24, 2025 at 6:01 PM
According to recent findings, erythroid-predominant #MyelodysplasticSyndromes #MDS, found to be characterized by frequent multi-hit #TP53 alterations and BCL-XL upregulation, is also associated with poor outcomes after #venetoclax-based therapy: https://ow.ly/HAMr50XwV6o
#HemeSky
#HemeSky
Combination treatment with #talquetamab plus #daratumumab demonstrated deep, durable responses in patients with heavily pretreated R/R #MMsm #myeloma, with 71% and 82% achieving a response, and safety consistent with each as monotherapy: https://ow.ly/cSkt50Xv8vP
#HemeSky #MyelomaSky #OncSky
#HemeSky #MyelomaSky #OncSky
November 21, 2025 at 3:02 PM
Combination treatment with #talquetamab plus #daratumumab demonstrated deep, durable responses in patients with heavily pretreated R/R #MMsm #myeloma, with 71% and 82% achieving a response, and safety consistent with each as monotherapy: https://ow.ly/cSkt50Xv8vP
#HemeSky #MyelomaSky #OncSky
#HemeSky #MyelomaSky #OncSky
In a small study of #pediatric patients with high-risk #AML, the combination of FLAG-IDA plus #venetoclax appeared to be a highly effective frontline treatment regimen, with all patients achieving CR and most proceeding to #hematopoietic cell #transplant: https://ow.ly/a1Cm50Xu4Xv
#HemeSky #leukemia
#HemeSky #leukemia
November 19, 2025 at 3:05 PM
In a small study of #pediatric patients with high-risk #AML, the combination of FLAG-IDA plus #venetoclax appeared to be a highly effective frontline treatment regimen, with all patients achieving CR and most proceeding to #hematopoietic cell #transplant: https://ow.ly/a1Cm50Xu4Xv
#HemeSky #leukemia
#HemeSky #leukemia
Airborne Ailments: Air #pollution from oil and gas affects the health and well-being of thousands of Americans each year. A study found that air pollution contributes to 1,610 #cancer cases annually.
#OncSky #MedSky
#OncSky #MedSky
November 18, 2025 at 5:10 PM
Airborne Ailments: Air #pollution from oil and gas affects the health and well-being of thousands of Americans each year. A study found that air pollution contributes to 1,610 #cancer cases annually.
#OncSky #MedSky
#OncSky #MedSky
FT516, an engineered, off-the-shelf NK cell product derived from induced pluripotent stem cells, demonstrated meaningful clinical activity in patients with R/R B-cell #lymphomas in a phase I trial, with an ORR of 58%, along with a favorable safety profile: https://ow.ly/7AMq50XqMof
#HemeSky #OncSky
#HemeSky #OncSky
November 13, 2025 at 5:02 PM
FT516, an engineered, off-the-shelf NK cell product derived from induced pluripotent stem cells, demonstrated meaningful clinical activity in patients with R/R B-cell #lymphomas in a phase I trial, with an ORR of 58%, along with a favorable safety profile: https://ow.ly/7AMq50XqMof
#HemeSky #OncSky
#HemeSky #OncSky
A new, more sensitive #assay used to find KIT p.D816V, a critical mutation in #MCAS and #mastocytosis, could improve disease detection and diagnosis by identifying cases of disease that are more difficult to find through other means or are undetectable: https://ow.ly/bxWV50XpHwm
#HemeSky #MedSky
#HemeSky #MedSky
November 12, 2025 at 2:30 PM
A new, more sensitive #assay used to find KIT p.D816V, a critical mutation in #MCAS and #mastocytosis, could improve disease detection and diagnosis by identifying cases of disease that are more difficult to find through other means or are undetectable: https://ow.ly/bxWV50XpHwm
#HemeSky #MedSky
#HemeSky #MedSky
Among patients with #MultipleMyeloma #MMsm treated with conventional #chemotherapy, #proteasome inhibitors, and/or #immunomodulatory agents, long-term PFS was found to be associated with achieving complete response and being diagnosed at a younger age: https://ow.ly/eMNC50Xon5h
#HemeSky #OncSky
#HemeSky #OncSky
November 7, 2025 at 3:20 PM
Among patients with #MultipleMyeloma #MMsm treated with conventional #chemotherapy, #proteasome inhibitors, and/or #immunomodulatory agents, long-term PFS was found to be associated with achieving complete response and being diagnosed at a younger age: https://ow.ly/eMNC50Xon5h
#HemeSky #OncSky
#HemeSky #OncSky